Nirav Shah, MD, discusses long-term data from the phase 1/2 BRUIN study which evaluated pirtobrutinib in mantle cell lymphoma, and next steps for evaluating the agent.
Nirav N. Shah, MD
Advertisement
Articles by Nirav N. Shah, MD
Nirav N. Shah, MD, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor T cells in a phase 1 dose escalation and expansion trial for relapsed B cell malignancies.
Advertisement
Latest Updated Articles
Pirtobrutinib Produces Durable Responses in Pretreated MCLPublished: November 5th 2023 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
